Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer
10.3971/j.issn.1000-8578.2024.24.0147
- VernacularTitle:白蛋白结合型紫杉醇或多西他赛联合卡铂新辅助治疗HER2阳性乳腺癌疗效比较
- Author:
Xin HAO
1
;
Chongzhu HU
2
;
Ruixue YUE
2
;
Tianpei MIAO
1
;
Zhong LI
1
Author Information
1. Department of Breast Surgery, The Affiliated Hospital of HeBei University, Baoding 071000, China.
2. The First Department of Breast Surgery, Baoding No.1 Central Hospital, Baoding 071000, China.
- Publication Type:CLINICALAPPLICATION
- Keywords:
Breast cancer;
Neoadjuvant therapy;
HER2;
Nab-paclitaxel;
Docetaxel;
Pathological complete response
- From:
Cancer Research on Prevention and Treatment
2024;51(9):779-783
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of trastuzumab plus pertuzumab (HP) combined with either nab-paclitaxel plus carboplatin or docetaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer in real-world clinical practice. Methods Clinical data of HER2-positive breast cancer patients who received neoadjuvant therapy with either HP combined with nab-paclitaxel plus carboplatin or HP combined with docetaxel plus carboplatin and subsequently underwent surgery were retrospectively collected from 11 tertiary grade-A hospitals in Hebei Province from June 2019 to December 2021. The total pathological complete response (tpCR) rates of the two groups were compared. Results A total of 76 patients were included in the study, with 47 in the nab-paclitaxel group and 29 in the docetaxel group. The tpCR rate was significantly higher in the nab-paclitaxel group than that in the docetaxel group (72.3% vs. 48.3%, χ2=4.463, P=0.035). Subgroup analysis indicated that patients older than 40 years, with cN2-3, cTNM stage Ⅲ, hormone receptor-positive status, and Ki67>30% had significantly higher tpCR rates in the nab-paclitaxel group than those in the docetaxel group (P<0.05). Conclusion In real-world clinical practice, the efficacy of HP combined with nab-paclitaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer is superior to that of HP combined with docetaxel plus carboplatin.
